Standard dosed abiraterone versus Therapeutic Drug Monitoring guided abiraterone dosing – The Adapt Abi trial

2025-524440-35-00 · tracked via the Priya Life Science EU tracker

Sponsor

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Sponsor type

Hospital/Clinic/Other health care facility

Therapeutic area

Neoplasms

Decision date

07/04/2026

Enrollment target

230

Sites

Netherlands

Condition studied

metastatic castration resistant prostate cancer (mCRPC)

Investigational medicinal product(s)

Abirateron Sandoz 500 mgfilmomhulde tabletten

Eligibility

Age group

65+ years, 18-64 years

Sex

Male

Primary endpoint

Radiographic progression-free survival (PFS)

Endpoint detail

Feasibility and safety of TDM, Physician adherence to TDM advice, Clinical progression, Overall response rates (ORR), Prostate Specific Antigen response rate (PSArr), PSA response at 12 weeks, Maximal PSA response, Time to PSA progression, Time on treatment (ToT), Overall survival (OS), Quality of life (QoL), Cost-effectiveness, Patient adherence, Toxicity (also in relationship to abiraterone concentrations and dose interventions)

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524440-35-00 on CTIS ↗ ← All trials in the EU